Business
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel
About this update from Sagimet Biosciences Inc. - Series A
[{"type":"text","content":"SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details: Poster Title:Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter:Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational SciencesSession:Poster Session 1; Vancouver Island RoomDate/Time:Monday, April 13, 2026, at 7:30 PM PTLocation:Fairmont Hotel, Vancouver, BC, Canada Presentation Title:Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter:Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational SciencesSession:Symposia Spotlight 2: Inflammation and Fibrosis in the Obese Liver, Columbia BallroomDate/Time:Wednesday, April 15, 2026, at 2:30-4:30 PM PTLocation:Fairmont Hotel, Vancouver, BC, Canada Poster and Presentation Highlights: Elevated serum bile acid levels have been associated with metabolic disorders such as MASH and type 2 diabetes. In Sagimet’s Phase 2b FASCINATE-2 clinical trial, denifanstat-treated MASH patients who were histological responders for both fibrosis regression and MASH resolution showed significant reduction in glycine- and taurine-conjugated bile acids at 26 weeks. These data suggest that these circulating bile acid levels may potentially be leveraged as a response biomarker in patients treated with denifanstat. Inducement Grant In connection with the hiring of an employee, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 9,600 stock options to purchase shares of the Company’s Series A common stock, be granted on April 3, 2026, to the newly hired employee. The option award was granted pursuant to th...